Arcturus Q1 net loss narrows to $14.1M; cash runway extends into 2028

Arcturus Therapeutics Holdings Inc.

2025-Q1 EPS reported -$0.52 revenue$29,382,000

Net loss $14.1M ($0.52/diluted share) vs $26.8M ($1.00) a year ago; revenue $29.4M down 23% YoY.
Cash, equivalents and restricted cash $273.8M at March 31, 2025; runway extended into 2028 via resource re-allocation.
Received initial EU approval milestone payment from CSL Seqirus for KOSTAIVE COVID-19 vaccine.
ARCT-032 (CF) Phase 2 interim data from first two cohorts expected mid-2025; enrollment to complete by year-end.
ARCT-810 (OTC) Phase 2 interim data expected Q2 2025; FDA Fast Track granted for H5N1 vaccine ARCT-2304.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.